| Literature DB >> 33086913 |
Florian P Thomas1, Mario Saporta2, Shahram Attarian3, Teresa Sevilla4, Rafael Sivera Mascaró5, Gian Maria Fabrizi6, Filippo Genovese7, Amy Gray8, Simon Bull9, Daniel Tanesse10, Manuel Rego11, Allison Moore12, Courtney Hollett12, Katia Monteiro13, Xavier Paoli13, Samuel Llewellyn14, Mark Larkin14, Youcef Boutalbi13.
Abstract
Charcot-Marie-Tooth disease (CMT) is a rare, chronic, progressive motor and sensory neuropathy affecting the peripheral nervous system. This study will explore the real-world impact of CMT. The trial is a digital study of approximately 2000 people in 6 countries with CMT ≥18 years. Participants will use a smartphone application to check eligibility, provide consent and contribute data. The dataset will include a personal profile, covering demographics, lifestyle, diagnosis and treatment and a selection of validated generic and disease-specific instruments. Participants will provide data for up to 2 years. Data analysis will be conducted upon registration of the 1000th participant and at 12-month intervals from launch. This study is designed to help researchers and clinicians understand the real-world impact of CMT and the unmet needs of patients. ClinicalTrials.gov identifier: NCT03782883.Entities:
Keywords: Charcot-Marie-Tooth disease; burden of illness; international; observational; patient-reported outcomes
Year: 2020 PMID: 33086913 DOI: 10.2217/nmt-2020-0044
Source DB: PubMed Journal: Neurodegener Dis Manag ISSN: 1758-2024